A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

Trial Profile

A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Brontictuzumab (Primary) ; Tipiracil/trifluridine (Primary) ; Trifluridine
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2017 Status changed from recruiting to discontinued because the combination of brontictuzumab plus chemotherapy was not tolerable in this patient population, according to an OncoMed Pharmaceuticals media release.
    • 20 Jan 2017 According to OncoMed Pharmaceuticals media release, the company has announced that first patient has been dosed.
    • 20 Jan 2017 Status changed from planning to recruiting according to OncoMed Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top